<DOC>
	<DOCNO>NCT00801905</DOCNO>
	<brief_summary>The purpose study determine whether topical nepafenac ( qid ) effective prevent treat macular thicken related pan-retinal photocoagulation patient diabetic retinopathy .</brief_summary>
	<brief_title>Effect Topical Nepafenac Macular Thickening Related Pan-Retinal Photocoagulation</brief_title>
	<detailed_description>Objective : To evaluate effect topical nepafenac 0.1 % , prevent treat macular thicken related pan-retinal photocoagulation diabetic patient . Material method : This prospective , longitudinal , control study patient diabetic retinopathy ( severe non-proliferative proliferative retinopathy ) , symmetric severity eye without clinical significant macular edema . The best corrected visual acuity ( BCVA ) patient 20/80 good . All patient undergo pan-retinal photocoagulation three different session ( 2 week apart ) . Each patient receive topical nepafenac 0.1 % ( qid ) one eye , placebo ( qid ) fellow eye , start 1 week first retinal photocoagulation session continue 9 week ( end 4 week pan-retinal photocoagulation complete ) . Spectral domain OCT BCVA ETDRS scale perform 2 week laser session , 1 , 2 3 month treatment complete . BCVA OCT outcomes study period compare eye , side effect record .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Patients Severe proliferative Diabetic Retinopathy Symmetric severity grade eye Best correct visual acuity well 20/80 Clinical significant macular edema Lens opacity Ocular surgery 6 month less recruit Uveitis history Actual use topical systemic nonsteroidal anti inflammatory agent Actual history macular disease Ocular surface diseases Vitreomacular traction syndrome Other vascular retinal disease different diabetic retinopathy Actual history use topical prostaglandin analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Macular thickening</keyword>
	<keyword>Macular edema</keyword>
	<keyword>Pan-retinal photocoagulation</keyword>
	<keyword>Nepafenac</keyword>
	<keyword>Topical non-steroidal anti inflammatory agent</keyword>
</DOC>